Update: Biovest Aims For BLA, Not NDA (OTC:BVTI)

Today, on 9/22/09, StocksHaven Investments had the opportunity of speaking to the Investor Relations representative at Biovest International Inc., Douglas W. Calder regarding the recent profile we conducted. A few minor erroneous details were present, and thus we are issuing a company verified update to clarify these issues.

The first problem at hand was that we mentioned it would be a new drug application, however, it is in fact a biologic license application or, for short BLA. So what is a BLA? A biologics license application is a submission that contains specific information on the manufacturing processes, chemistry, pharmacology, clinical pharmacology and the medical affects of the biologic product. If the information provided meets FDA requirements, the application is approved and a license is issued allowing the firm to market the product. Essentially, it is a formal application analogous to a New Drug Application, but for biotechnology-derived pharmaceuticals (for example, complex, large molecules).

Moreover, they are in fact expecting to have a face-to-face meeting with the FDA with regards to BiovaxID sometime in Q1 of 2010, afterwhich depending on the outcome, a BLA submission could follow shortly thereafter. Currently, Biovest is preparing an informational package for the FDA in order to share data on BiovaxID, and a number of other items, such as the manufacturing facility in Miniapolis Minnesota, analysis ongoing with the clinical studies related to immune response, mechanisms of action involving b-cells, t-cells, or perhaps combination of both. Douglas went on to state that, data points the FDA wants to see include the possibility of other predictors that can indicate a more likely outcome of success for the patient. During the meeting, Biovest will also discuss the possibilities of an accelerated approval process for BiovaxID.

Communication with the FDA is ongoing, and Biovest is paying close attention to the draft guidance issued for companies seeking approval with cancer vaccines which are unique to patients, and as well the section for granting of accelerated approval process.

On an ending note, it is important to keep into consideration that the company is under Chapter 11, thus there always exists the unlikely scenario that the current common shares may be cancelled.

Disclosure: Short position in BVTI

To feature your publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

###

About StocksHaven Investments

StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

Michael Vlaicu

Founder and Lead Investment Analyst

StocksHaven Investments

Contact via E-mail